

Index

- ACTH. *See* adrenocorticotrophic hormone
- adoption, 191
- adrenal system. *See* adrenarche
- adrenarche, 8
- cortisol production, 8
- dehydroepiandrosterone, 8
- DHES, 8
- premature, 8
- adrenocorticotrophic hormone (ACTH), 6
- AH. *See* assisted hatching
- AIS. *See* androgen insensitivity syndrome
- AMH. *See* anti-Müllerian hormone
- androgen deficiency, in males, 24
- androgen insensitivity syndrome (AIS), 201–202
- andropause, 24
- animal sperm cells, 1
- anti-Müllerian hormone (AMH)
- fetal gonad development, 5
- in folliculogenesis, 34
- ovarian stimulation and, 72–73
- antral follicle count, 49
- ovarian stimulation and, 72–73
- apical follicle wall breakdown, 40
- arcuate nuclei (ARC), 8–9
- ART. *See* artificial reproductive technologies
- artificial insemination. *See also* intrauterine insemination
- in animals, early examples of, 1
- animal sperm cells, 1
- artificial reproductive technologies (ART), 46, 48. *See also* cryopreservation; *in vitro* fertilization; intracytoplasmic sperm injection
- social, 81
- success rates for, 182
- assisted hatching (AH), 130–131
- laser-assisted, 130
- atretic follicles, 38–39
- azoospermia, 169–172
- clinical definition of, 169
- etiology of, 172
- genetic counseling for, 177–178
- hormone replacement therapy for, 177
- mTESA procedure, 177
- non-obstructive, 169, 173–176
- clomiphene citrate treatment, 176
- genetic counseling for, 177–178
- genetic testing for, 178, 198–199
- histological diagnosis of, 173
- testicular microdissection for, 174–176
- obstructive, 169–171, 172–173
- chromosomal composition and, 173
- microsurgical epididymal sperm aspiration for, 172–173
- stimulation for spermatogenesis with, 176–177
- testicular fine-needle aspiration, 171–172
- testicular germ cell tumor, 172
- testicular sperm aspiration, 171–172
- transrectal ultrasound for, 171
- balanced translocations, in chromosomes, 196
- Barr bodies, 3
- biopsy. *See also specific topics*
- with genetic material aspiration
- for blastocysts, 210–211
- for blastomeres, 209–210
- for polar body, 209
- for trophoctoderm, 210–211
- for PGT, 208
- with zona pellucida opening
- chemical biopsy, 208
- contact laser biopsy, 208–209
- blastocysts
- biopsy of, 210–211
- cryopreservation of, 147–148
- in embryo culture, 119–123
- classification by size, 122
- blastomeres
- biopsy of, with genetic material aspiration, 209–210
- in embryo culture, 121
- blepharophimosis, ptosis, and epicanthus inversus (BPES), 201
- Brawn, Louise, 78
- Brinster, Ralph, 114
- bromocriptine, 81
- Brown, Louise Joy, 1–2
- bulbourethral glands. *See* Cowper's glands
- cabergoline, 81
- capacitation, of sperm cells, 22
- catheter use, in embryo transfer, 132–134
- depth of catheters, in uterus, 133–134
- expulsion speed issues, 134–135
- loading options for, 133, 134
- time frame of embryo in, 133
- CBAVD. *See* congenital bilateral absence of vas deferens
- central nervous system (CNS), puberty and, 8
- CGH. *See* comparative genomic hybridization
- chemical biopsy, 208
- Chen, Christopher, 148
- chromosomal microarray (CMA), 215
- comparative genomic hybridization, 216–217
- chromosomes, 194
- fetal gonad development and, aberrations in, 6
- mutation-based disorders, 195
- in obstructive azoospermia, 173
- organization of, 194
- PGT and, screening for, 207
- reproductive aging, in females, abnormalities from, 48
- sex, in embryo reproductive systems, 3
- structural rearrangement, 196–197
- deletions, 196–197
- duplications, 196–197
- inversions and rings, 196–197
- mosaicism, 197
- translocations in, 196
- uniparental disomy, 196–197
- X chromosome
- inactivation of, 196
- mutations of, 195–196
- CL. *See* corpus luteum
- classic IVF, 102–103
- micromanipulation techniques, 103
- partial zona dissection in, 103

Index

- classic IVF (cont.)
 subzonal insemination in, 103
 cleavage embryo cryopreservation, 147
 clomiphene citrate, 73–74
 for non-obstructive azoospermia, 176
 CMA. *See* chromosomal microarray
 CNS. *See* central nervous system
 COC collection. *See* cumulus-oocyte complex collection
 comparative genomic hybridization (CGH), 216–217
 conception
 embryo development, 57
 embryogenesis in, 66
 embryonic germ layers, formation of, 66–67
 anomalies in development, 67
 ectoderm, 66
 endoderm, 66
 mesoderm, 66
 fertilization, 56–57
 endometrium receptivity, 61, 62
 location of, 56
 paternal mitochondrial DNA reduction in, 57
 sperm and oocyte membrane fusion, 56–57
 trophoblast invasion, 61–62
 implantation, 57–62
 attachment-detachment events, 59–60
 ectopic pregnancy, 61–62
 embryo-uterine interaction, 59–60
 epithelial morphology, 58–59
 human CG regulation, 60–61
 in placenta, 63, 66
 window, 58–59
 organogenesis in, 64–65
 placenta during, 62–66
 embedded within decidua, 62–66
 function and purpose of, 62
 immune system in, 63–66
 implantation in, 63, 66
 maternal tolerance, 65–66
 structure of, 63
 pregnancy periods, 66
 congenital bilateral absence of vas deferens (CBAVD), 201
 contact laser biopsy, 208–209
 controlled ovarian hyperstimulation, 71, 73, 75–78
 GnRH analogs for, agonist/antagonist protocols for, 76–78
 human menopausal gonadotropins, 75–76
 IVF and, 76–77, 78
 recombinant gonadotropins, 76
 corpus luteum (CL)
 composition and structure of, 43
 development of, 41–44
 functions of, 41, 43, 85
 luteal phase, in stimulated cycles, 85
 for IVF, 85
 luteal progesterone
 supplementation, 85–87
 duration of support, 86–87
 intramuscular administration, 86
 oral administration, 86
 rectal administration, 86
 subcutaneous administration, 86
 vaginal administration, 86
 luteolysis, 42, 43–44
 cortisol production, adrenarche and, 8
 Cowper's glands (bulbourethral glands), 21, 24
 CPAs. *See* cryoprotective additives
 CPEB proteins. *See* cytoplasmic polyadenylation element-binding proteins
 cryopreservation
 of blastocysts, 147–148
 cleavage embryo, 147
 cryoprotective additives for, types of, 144–146
 toxicity of, 145
 development of, 144
 gender identity disorder and, 154
 mechanisms of, 144–146
 of preparation, 146
 of oocytes, 148–149
 donation of, 185
 for metaphase-II oocytes, 148–149
 risk factors in, 148
 for social oocytes, 149
 thawing processes for, 149–150
 of ovarian tissue, 150–152
 disadvantages of, 152
 mosaic Turner syndrome and, 150
 thawing processes for, 151
 transplantation after, 152
 vitrification methods, 151
 slow, 144
 of sperm cells, 152–154
 in intracytoplasmic sperm injection, 153–154
 mechanisms of, 153
 in percutaneous epididymal sperm aspiration, 153–154
 risk factors for, 153
 spermatogonial stem cells, 154
 success rates with, 153
 in testicular aspiration, 153–154
 testicular tissue banking, 154
 thawing processes, 149–150
 for ovarian tissue, 151
 vitrification methods, 145, 148
 with ovarian tissue, 151
 of zygotes, 147
 thawing processes for, 149–150
 cryoprotective additives (CPAs), 144–146
 toxicity of, 145
 cryptorchidism, 202
 cumulus-oocyte complex (COC)
 collection, 91
 empty follicle syndrome and, 92
 cytoplasmic polyadenylation element-binding (CPEB) proteins, 44
 dark type A spermatogonia, 16, 17
 decidualization, in embryo transfer, 137
 defective ovulation, infertility from, 73
 hypogonadotropism-associated, 73
 Kallmann syndrome, 73
 dehydroepiandrosterone (DHEA), 8
 for hormonal ovarian treatment, 80
 with diminished ovarian reserve, 80
 DHES, 8. *See also*
 dehydroepiandrosterone
 dihydrotestosterone (DHT), 5–6
 diminished ovarian reserve (DOR), 80
 donation, donors and. *See also*
 surrogacy
 of embryos, 186
 medical history of, 182–184
 of oocytes, 185–186
 age risks for, 186
 through cryopreservation, 185
 donor protocols, 185–186
 recipient protocols, 186
 risk factors for, 185
 success rates for, 185
 with transvaginal ultrasound-guided follicular aspiration, 185
 of ooplasm, 186–188
 mitochondrial DNA and, 187–188
 oogonial stem cells, 187–188
 social status and, 184
 sperm, 183–185
 genetic testing of, 184
 limitation of, 184
 record management for, 184–185
 success rates for, 184
 DOR. *See* diminished ovarian reserve
 double-witnessing, for
 preimplantation genetic testing, 211
 ectoderm, 66
 ectopic pregnancy, 61–62
 Edwards, Robert, 1–2, 85
 EFS. *See* empty follicle syndrome
 ejaculate, in males, 21–23
 coagulation of, outside of body, 21–22
 Cowper's glands and, 21, 24
 emission mechanisms for, 21

- embryo culture
 day 1 of, with zygotes, 116–118, 121
 tetrapronuclear zygotes, 116, 118
 tripronuclear zygotes, 116, 118
 day 2 of, with 2–4 cells, 118–119, 121
 day 3 of, with 6–8 cells, 119, 121
 day 4 of, as morula, 119, 121
 day 5 of, as blastocyst, 119–123
 classification by blastocyst size, 122
 excretion products, 120
 historical development of, 114
 media preparation for, 114–116
 amino acids in, 114–115
 growth factors in, 115
 micro-drop method, 114
 one-step, 116
 timing for optimal embryonic development stages, 123
 two-step, 116
 uptake products, 120
 embryo transfer (ET)
 with assisted hatching, 130–131
 laser-assisted, 130
 bed-rest after, 135
 catheters in, 132–134
 depth of, in uterus, 133–134
 expulsion speed issues, 134–135
 loading options for, 133, 134
 time frame of embryo in, 133
 as donation, 186
 embryo selection in, 127–129
 at blastocyst stage, 128
 meiotic errors and, 128
 mitotic errors and, 128
 morphological assessment for, 128, 130
 endometrial injury, 138
 endometrial suitability for, 137
 contamination risks, 137
 decidualization, 137
 transcervical procedures as influence on, 137
 environmental factors for, 126–127
 of frozen-thawed embryos, 136
 fresh embryos compared to, 136
 hormonal replacement treatment and, 136
 gamete intra-Fallopian transfer, 127
 hyaluronic acid in, 135
 implantation rates in, 136–137
 monozygotic twinning, 136
 multiple pregnancy rate, 136
 single embryo transfer, 136–137
 intercourse during, 137
 intra-uterine embryo transfer, 127
 oviduct conditions for, 126–127
 transfer procedures, 131–132
 delays to, 135–136
 timing of, 135–136
 uterine conditions for, 126–127
 zygote intra-Fallopian transfer, 127
 embryogenesis, 66
 embryology, definition of, 2
 embryonic germ layers, formation of, 66–67
 anomalies in development, 67
 ectoderm, 66
 endoderm, 66
 mesoderm, 66
 embryos. *See also* embryo transfer
 in conception, development of, 57
 embryogenesis, 66
 reproductive system development in, 4. *See also* fetal gonads; fetal ovaries
 Barr bodies, 3
 sex chromosomes, 3
 empty follicle syndrome (EFS), 92
 cumulus-oocyte complex collection, 92
 media preparation for, 92
 endoderm, 66
 endometrium, in embryo transfer
 contamination risks, 137
 decidualization, 137
 injury risks, 138
 suitability factors, 137
 transcervical procedures as influence on, 137
 endometrium receptivity, 61, 62
 epididymis, 19–20
 functionally-different regions of, 20
 hormonal control and, 20
 sexually-transmitted diseases and, 20
 sperm cell motility and, 20
 estradiol, declines in, 47
 estrous cycle, 38
 ET. *See* embryo transfer
 Fallopian tubes, 31–32
 Fallopian, Gabrielis, 31–32
 female infertility, 198
 from defective ovulation, 73
 hypogonadotropism-associated, 73
 Kallmann syndrome, 73
 female reproductive system
 anatomy, 28
 atretic follicles, 38–39
 corpus luteum
 composition and structure of, 43
 development of, 41–44
 functions of, 41, 43
 luteolysis, 42, 43–44
 endocrine system rhythms, 28
 Fallopian tubes, 31–32
 follicular steroidogenesis, 37–38
 of estrous cycle, 38
 folliculogenesis, 32–37
 anti-Müllerian hormones, 34
 follicle-stimulating hormone, 33–34
 after gonadotropin surge, 41–44
 intercellular gap junctions, 34
 paracrine factors, 34
 stroma cells, 34
 gonadotropin surge
 folliculogenesis after, 41–44
 maturation of preovulatory follicle during, 41
 hormonal regulation of, 28
 follicle-stimulating hormones, 28
 GnRH and, 28
 hypothalamic-pituitary-gonads-hormonal axis, 28
 luteinizing hormones, 28
 puberty and, 28
 luteinizing hormones
 during ovulation, 39–40
 regulation of, 28
 maturation of preovulatory follicle, 39
 during gonadotropin surge, 41
 meiosis, 41
 Mayer-Rokitansky-Kuster-Hauser syndrome, 31
 meiosis, 44–46
 cytoplasmic polyadenylation element-binding proteins, 44
 incomplete, 44–45
 maturation of preovulatory follicle, 41
 resumption of, 46
 menstruation, 44
 shortening of cycles, 47–48
 oocyte growth, 37
 through meiosis, 46
 molecule transfer, 37
 ZP of, 37
 ovaries, 32
 fertility and, 32
 follicular growth, 32, 35–36
 menstrual cycle, 33, 35–36
 structure of, 32
 ovulation, 39–41
 apical follicle wall breakdown, 40
 luteinizing hormone surge, 39–40
 reproductive aging. *See* reproductive aging
 uterus, 31
 structure of, 31
 vaginal microbiota, 31
 vagina, 28–31
 vaginal microbiota, 28–31
 females, onset of puberty for, 8
 fertility. *See also* female infertility; male infertility
 ovary health and, 32

Index

- fertilization, conception and, 56–57
 endometrium receptivity, 61, 62
 location of, 56
 paternal mitochondrial DNA
 reduction in, 57
 sperm and oocyte membrane fusion,
 56–57
 trophoblast invasion, 61–62
 FET. *See* frozen-thawed embryo
 transfer
 fetal gonads, development of, 3, 4–6
 adrenocorticotrophic hormone, 6
 anti-Müllerian hormone secretions, 5
 chromosomal aberrations and, 6
 dihydrotestosterone, 5–6
 human chorionic gonadotropin, 6
 Leydig cell hypertrophy, 5–6
 Müllerian-inhibiting substance, 5
 somatic cells in, 3–4
 testes-determining factor, 4–5
 testosterone presence, 5–6
 fetal ovaries, development of, 3–4
 follicle-stimulating hormone and, 4
 germ cell nest breakdown, 4
 Müllerian hormones, 3
 oocyte development, 4, 6
 primordial germ cells in, 3
 stages of development, 3
 fluorescence in situ hybridization
 (FISH), 214–215
 follicle-stimulating hormone (FSH), 11
 in female reproductive system,
 regulation of, 28
 in fetal ovary development, 4
 in folliculogenesis, 33–34
 Sertoli cells and, 14–15
 follicular steroidogenesis, 37–38
 of estrous cycle, 38
 folliculogenesis, 32–37
 anti-Müllerian hormones, 34
 follicle-stimulating hormone, 33–34
 after gonadotropin surge, 41–44
 intercellular gap junctions, 34
 paracrine factors, 34
 stroma cells, 34
 46, XX male syndrome, 199
 Fragile-X syndrome, 201
 frozen-thawed embryo transfer (FET),
 136
 frozen-thawed embryos, embryo
 transfer of, 136
 fresh embryos compared to, 136
 hormonal replacement treatment
 and, 136
 FSH. *See* follicle-stimulating hormone
 gender identity disorder (GID), 154
 genetic counseling
 for azoospermia, 177–178
 for infertility, 203–204
 genetic material aspiration (GMA),
 209–211
 advanced molecular methods for,
 210
 blastocyst biopsy, 210–211
 blastomere biopsy, 209–210
 polar body biopsy, 209
 trophectoderm biopsy, 210–211
 genetic testing, 197–200. *See also*
 preimplantation genetic testing
 for androgen insensitivity
 syndrome, 201–202
 for autosomal translocation, 200
 blepharophimosis, ptosis, and
 epicanthus inversus, 201
 for congenital bilateral absence of
 vas deferens, 201
 for cryptorchidism, 202
 cytogenetic analysis through,
 198–200
 of female infertility, 198
 for 46, XX male syndrome, 199
 for Fragile-X syndrome, 201
 for hypogonadism, 203
 for Jacob's syndrome, 199
 for Klinefelter syndrome, 198–199
 of male infertility, 197–200. *See also*
 specific disorders and syndromes
 from genetic defects, 202–203
 from monogenic mutations, 201.
 See also specific syndromes and
 disorders
 for non-obstructive azoospermia,
 178, 198–199
 Y chromosome microdeletions,
 200–201
 for sex-chromosome translocation,
 200
 steroid 5- α -reductase 2
 deficiencies, 202
 for Turner syndrome, 199
 for XXX syndrome, 199
 for YO syndrome, 199–200
 genetics, reproduction and. *See also*
 chromosomes; genetic testing
 mitochondrial DNA and, 196
 mutations, types of, 194–196
 chromosomal disorders from, 195
 dominant, 194–195
 monogenic, 195–196
 multifactorial disorders from, 195
 recessive, 194
 on X chromosome, 195–196
 germ cell nest breakdown, 4
 gestational surrogacy, 188
 cycles of, 188
 GID. *See* gender identity disorder
 GMA. *See* genetic material aspiration
 GnRH-secreting neurons, 9–11
 in female reproductive system, 28
 gonadarche
 arcuate nuclei, 8–9
 follicle-stimulating hormone, 11
 GnRH-secreting neurons, 9–11
 hypothalamic-pituitary axis, 8–11
 kisspeptin receptors, 8–9
 luteinizing hormone, 8–9, 11
 gonadotropin surge, in female
 reproductive system
 folliculogenesis after, 41–44
 maturation of preovulatory follicle
 during, 41
 Graaf, Rainier de, 31–32
 Hartsoeker, Nicolaas, 1, 2
 hCG. *See* human chorionic
 gonadotropin
 HLA typing, 219
 hormonal ovarian treatment
 for controlled ovarian
 hyperstimulation, 71, 73, 75–78
 GnRH analogs for, agonist/
 antagonist protocols for, 76–78
 human menopausal
 gonadotropins, 75–76
 IVF and, 76–77, 78
 recombinant gonadotropins, 76
 for defective ovulation, infertility
 from, 73
 hypogonadotropism-associated,
 73
 Kallmann syndrome, 73
 with dehydroepiandrosterone
 supplementation, 80
 with diminished ovarian reserve,
 80
 induction of final oocyte maturation,
 78–79
 IVF and
 controlled ovarian
 hyperstimulation and, 76–77,
 78
 spontaneous cycle, 78
 ligand-receptor interaction, 71
 receptor agonists, 71, 72
 management of disorders, 79
 natural ovarian cycles, 78
 modified, 78
 oocytes per stimulatory cycle,
 optimal number of, 79
 for ovarian hyperstimulation
 syndrome, 81
 human chorionic gonadotropin
 administration for, 81
 primary risk factors, 81
 secondary risk factors, 81
 treatment options for, 81
 ovarian induction, 71, 73
 clomiphene citrate for, 73–74
 letrozole for, 74

- ovarian stimulation, 71–73
 - anti-Müllerian hormone in, 72–73
 - antral follicle count, 72–73
 - mild, 78
- ovarian superovulation, 71, 73
 - for intrauterine insemination, 74–75
- with polycystic ovary syndrome, 79–80
- side effects of, 80–81
- social artificial reproductive technologies, 96
- two-cell theory, 71
- two-gonadotropin theory, 71
- hormone replacement therapy (HRT)
 - for azoospermia, 177
 - frozen-thawed embryos and, 136
- human chorionic gonadotropin (hCG), 6
 - for ovarian hyperstimulation syndrome, 81
- regulation of, during conception, 60–61
- two-gonadotropin theory, 71
- human embryo implantation. *See also*
 - in vitro fertilization
 - Edwards and, 1–2
 - Steptoe and, 1–2
- hyaluronic acid, 105–106
- hypogonadism, 203
- hypogonadotropism-associated
 - defective ovulation, 73
- hypothalamic-pituitary system
 - in female reproductive system, 28
 - gonadarche, 8–11
- ICSI. *See* intracytoplasmic sperm injection
- implantation. *See* conception
- implantation window, 58–59
- in vitro activation (IVA) of ovary, 165
- in vitro fertilization (IVF). *See also*
 - intracytoplasmic sperm injection; *specific topics*
 - classic, 102–103
 - micromanipulation techniques, 103
 - partial zona dissection in, 103
 - subzonal insemination in, 103
- early pioneers of, 1–2
- fertilization process, 101–102
 - by intrauterine insemination, 102
- first “test tube baby,” 1–2
- hormonal ovarian treatment and controlled ovarian
 - hyperstimulation and, 76–77, 78
 - spontaneous cycle, 78
- oocytes preparation, 98–99
 - damages in, after stripping, 101
- denudation of oocytes, for ICSI, 98–99
 - morphology of oocytes, 100
- origin of, 1
- preparation for, 95
- sperm preparation, 95–98
 - magnetic activated cell sorting, 97–98
 - migration-sedimentation technique, 96–97
 - specimen collection, 95
 - specimen measurements, 96
 - sperm density gradient centrifugation, 97
 - swim-down technique, 97
 - swim-up technique, 96
- types of, 103
- in vitro laboratories
 - air quality and ventilation in, 227–228
 - countertops in, 232
 - floors in, 232
 - hand-washing facilities, 233
 - humidity control in, 233
 - identification controls, 233
 - incubators, 228–231
 - gas supply in, 231
 - oil overlay, 231
 - time-lapse imaging, 229–231
 - traditional, 228–229
 - for intracytoplasmic sperm injection, 228
 - laminar flow workstations, 228
 - lighting in, 232
 - quality management for, 234–235
 - national and international programs for, 234
 - safety protocols, 235
 - semen treatment management, 233
 - staffing for, 235–236
 - standard operating procedures for, 234
 - structure of, 226–227
 - temperature setting in, 232–233
 - virus contamination in, 232
 - walls in, 232
- in vitro maturation (IVM)
 - development of, 159
 - follicle maturation, 164–165
 - in vitro activation of ovary, 165
 - of oocytes, *in vitro*, 163–164
 - classical protocols for, 163
 - follicle aspiration techniques, 163
 - with polycystic ovary syndrome, 163–164
 - success rates for, 164
 - of oocytes, *in vivo*, 159–162
 - during meiosis, 159–161, 162
 - metabolism of, 162–163
 - MPF regulation, 160–161
 - Type I, 161–162
 - Type II, 162
 - Type III, 162
- incomplete meiosis, 44–45
- incubators, in *in vitro* laboratories, 228–231
 - gas supply in, 231
 - oil overlay, 231
 - time-lapse imaging, 229–231
 - traditional, 228–229
- infertility
 - female, 198
 - from defective ovulation, 73
 - hypogonadotropism-associated, 73
 - Kallmann syndrome, 73
 - genetic counseling for, 203–204
 - historical record of, 1
 - male. *See* male infertility
 - inhibin-B declines, 47
- insemination. *See* artificial insemination
- intracytoplasmic sperm injection (ICSI), 103–108
 - abnormalities after fertilization, 107
 - congenital malformations with, 108
 - cryopreservation of sperm cells and, 153–154
 - early applications of, 103–104
 - laboratory for, 228
 - laboratory setting for, 228
 - oocytes in
 - denudation of, 98–99
 - survival rate of, 104
 - prenatal diagnosis after pregnancy, 108
 - safety of, 108
 - sperm selection and preparation in, 104–107
 - after assisted ejaculation, 107
 - hyaluronic acid and, 105–106
 - through magnetic activated cell sorting, 105
 - after penile vibratory stimulation, 107
 - after retrograde ejaculation, 106
 - semen viscosity, 106
 - timing of, 104
- intrauterine insemination (IUI), 74–75
- IVF by, 102
- IVA. *See* in vitro activation of ovary
- IVF. *See* in vitro fertilization
- IVM. *See* in vitro maturation
- Jacob’s syndrome, 199
- Kallmann syndrome, 73
- karyomapping, 218–219
- kisspeptin receptors, 8–9
- Klinefelter syndrome, 198–199

Index

- laser biopsy. *See* contact laser biopsy
 laser-assisted assisted hatching, 130
 late-onset hypogonadism, 24
 letrozole, 74
 Leydig, Franz von, 13
 Leydig cells
 hypertrophy of, 5–6
 oxytocin production, 13
 testosterone bioavailability in, 13
 LH. *See* luteinizing hormone
 luteal progesterone supplementation,
 85–87
 duration of support, 86–87
 intramuscular administration, 86
 oral administration, 86
 rectal administration, 86
 subcutaneous administration, 86
 vaginal administration, 86
 luteinizing hormone (LH), 8–9, 11
 in female reproductive system, 28
 during ovulation, 39–40
 luteolysis, 42, 43–44
- magnetic activated cell sorting
 (MACS), 97–98
 intracytoplasmic sperm injection
 and, 105
- male infertility. *See also* azoospermia;
 sperm cells
 from androgen insensitivity
 syndrome, 201–202
 from blepharophimosis, ptosis, and
 epicanthus inversus, 201
 from congenital bilateral absence of
 vas deferens, 201
 from cryptorchidism, 202
 from 46, XX male syndrome, 199
 from Fragile-X syndrome, 201
 genetic testing for, 197–200
 from genetic defects, 202–203
 for monogenic mutations, 201
 for non-obstructive azoospermia,
 178, 198–199
 Y chromosome microdeletions,
 200–201
 from hypogonadism, 203
 from Jacob's syndrome, 199
 from Klinefelter syndrome, 198–199
 from steroid 5-alpha-reductase 2
 deficiencies, 202
 from Turner syndrome, 199
 from XXX syndrome, 199
 from Y0 syndrome, 199–200
- male reproductive system, physiology
 of, 14
 accessory glands, 24
 Cowper's glands, 21, 24
 early development of, 13
 ejaculate, 21–23
 coagulation of, outside of body,
 21–22
 Cowper's glands and, 21, 24
 emission mechanisms for, 21
 epididymis, 19–20
 functionally-different regions of,
 20
 hormonal control and, 20
 sexually-transmitted diseases and,
 20
 sperm cell motility and, 20
 hormonal axis in, 15
 prostate gland, 23
 reproductive aging, 24–25
 androgen deficiency, 24
 andropause, 24
 late-onset hypogonadism, 24
 potency and sexual interest and,
 decline in, 25
 testosterone levels, decreases in,
 24
 seminal vesicles, 23
 semenogelin, 23
 sperm cells
 acrosome reaction, 23
 capacitation of, 22
 count for, variability in, 19
 discovery of, 21
 motility of, 20
 structure of, 21
 spermatogenesis, 15–19
 dark type A spermatogonia, 16, 17
 DNA condensation, 18–19
 pale type A spermatogonia, 16, 17
 sperm cell count, variability in, 19
 spermiogenesis, 18–19
 type B spermatogonia, 16–18
 testes, 13–15
 Leydig cells, 13–14
 Sertoli cells, 14–15, 20
 structure of, 15
 testosterone secretion patterns, 15
 vascular system, 20–21
 males, onset of puberty for, 8
 Mantegazza, Paolo, 152
 massive parallel sequencing. *See* next-
 generation screening
 maturation of preovulatory follicle, 39
 during gonadotropin surge, 41
 meiosis, 41
 Mayer-Rokitansky-Kuster-Hauser
 (MRKH) syndrome, 31,
 188–189
 meiosis, 44–46
 cytoplasmic polyadenylation
 element-binding proteins, 44
 in vitro maturation during, 159–161,
 162
 incomplete, 44–45
 in male gametes compared to female
 gametes, 45
 in maturation of preovulatory
 follicle, 41
 resumption of, 46
 meiotic errors, in embryo transfer, 128
 Menkin, Miriam, 1–2
 menopause, 46–47, 53
 menstruation, 44
 ovary health and, 33, 35–36
 shortening of cycles, 47–48
 MESA. *See* microsurgical epididymal
 sperm aspiration
 mesoderm, 66
 metaphase-II (M-II) oocytes, 148–149
 microsurgical epididymal sperm
 aspiration (MESA), 172–173
 migration-sedimentation technique,
 96–97
 M-II oocytes. *See* metaphase-II oocytes
 mild ovarian stimulation, 78
 MIS. *See* Müllerian-inhibiting
 substance
 mitochondrial DNA (mtDNA)
 instability of, 48
 in ooplasm donation, 187–188
 paternal, 57
 preimplantation genetic testing for,
 220
 mitotic errors, in embryo transfer, 128
 morula, in embryo culture, 119, 121
 mosaic Turner syndrome, 150
 mosaicism, 197, 218
 MPR. *See* multiple pregnancy rate
 MRKH syndrome. *See* Mayer-
 Rokitansky-Kuster-Hauser
 syndrome
 mtDNA. *See* mitochondrial DNA
 mTESE. *See* testicular microdissection
 Müllerian hormones, in fetal ovary
 development, 3
 Müllerian-inhibiting substance (MIS),
 5
 multiple pregnancy rate (MPR), 136
- next-generation screening (NGS), 215
 PGT-A by, 217–219
 NOA. *See* non-obstructive
 azoospermia
 non-invasive preimplantation genetic
 testing, 220
 non-obstructive azoospermia (NOA),
 169, 173–176
 clomiphene citrate treatment, 176
 genetic counseling for, 177–178
 genetic testing for, 178, 198–199
 histological diagnosis of, 173
 testicular microdissection for,
 174–176

- obstructive azoospermia (OA),
 169–171, 172–173
 chromosomal composition and, 173
 microsurgical epididymal sperm
 aspiration for, 172–173
 OHSS. *See* ovarian hyperstimulation
 syndrome
 oocyte development
 in female reproductive system, 37
 through meiosis, 46
 molecule transfer, 37
 ZP of, 37
 in fertilization, sperm fusion and,
 56–57
 in fetal ovaries, 4, 6
 morphology of, 100
 reproductive aging and, in females,
 48
 oocyte preparation
 in intracytoplasmic sperm injection
 denudation of oocytes, 98–99
 survival rate of, 104
 in IVF, 98–99
 damages in, after stripping, 101
 denudation of oocytes, for ICSI,
 98–99
 morphology of oocytes, 100
 oocytes
 cryopreservation of, 148–149
 donation and, 185
 for metaphase-II oocytes, 148–149
 risk factors in, 148
 for social oocytes, 149
 thawing processes for, 149–150
 donation of. *See* donation
 in vitro maturation of. *See* in vitro
 maturation
 oogonial stem cells (OSC), 187–188
 ooplasm, donation of, 186–188
 mitochondrial DNA and, 187–188
 oogonial stem cells, 187–188
 OPU. *See* ovum pick-up
 organogenesis, in conception, 64–65
 OSC. *See* oogonial stem cells
 ovarian hyperstimulation syndrome
 (OHSS), 81
 human chorionic gonadotropin
 administration for, 81
 primary risk factors, 81
 secondary risk factors, 81
 treatment options for, 81
 ovarian induction, 71, 73
 clomiphene citrate for, 73–74
 letrozole for, 74
 ovarian stimulation, 71–73
 anti-Müllerian hormone in, 72–73
 antral follicle count, 72–73
 mild, 78
 ovarian superovulation, 71, 73
 for intrauterine insemination, 74–75
 ovarian tissue, cryopreservation of,
 150–152
 disadvantages of, 152
 mosaic Turner syndrome and, 150
 thawing processes for, 151
 transplantation after, 152
 vitrification methods, 151
 ovaries, 32. *See also* fetal ovaries;
 hormonal ovarian treatment
 fertility and, 32
 follicular growth, 32, 35–36
 menstrual cycle, 33, 35–36
 structure of, 32
 ovulation, 39–41
 apical follicle wall breakdown, 40
 luteinizing hormone surge, 39–40
 ovum pick-up (OPU), 90
 clinical process for, 89–90
 clinician's role, 89–90
 cumulus-oocyte complex collection,
 91
 empty follicle syndrome and, 92
 embryologist's role in, 90–91
 empty follicle syndrome, 92
 cumulus-oocyte complex
 collection, 92
 media preparation for, 92
 success rates for, 89
 oxytocin production, 13
 pale type A spermatogonia, 16, 17
 partial zona dissection (PZD), 103
 paternal mitochondrial DNA, 57
 PB biopsy. *See* polar body biopsy
 PCOS. *See* polycystic ovary syndrome
 penile vibratory stimulation (PVS),
 107
 percutaneous epididymal sperm
 aspiration (PESA), 153–154
 PGCs. *See* primordial germ cells
 PGT-A. *See* preimplantation genetic
 testing
 PGT-M. *See* preimplantation genetic
 testing
 PGT-SR. *See* preimplantation genetic
 testing
 Pincus, Gregory, 1–2
 placenta, during conception, 62–66
 embedded within decidua, 62–66
 function and purpose of, 62
 immune system in, 63–66
 implantation in, 63, 66
 maternal tolerance, 65–66
 structure of, 63
 polar body (PB) biopsy, 209
 Polge, Chris, 144
 polycystic ovary syndrome (PCOS),
 79–80
 in vitro maturation with, 163–164
 pregnancy
 ectopic, 61–62
 with intracytoplasmic sperm
 injection, prenatal diagnosis
 after, 108
 multiple pregnancy rate, 136
 periods of, 66
 through surrogacy, 188
 preimplantation genetic testing (PGT)
 accreditation factors for, 221
 analysis principles for, 211–214
 for PGT-M, 211–213
 for PGT-SR, 213–214
 biopsy for, 208
 with chromosomal microarray, 215
 comparative genomic
 hybridization, 216–217
 chromosomal screening for, 207
 cycle follow-up, 220–221
 double witnessing for, 211
 fertilization methods for, 207
 with fluorescence in situ
 hybridization, 214–215
 genetic material aspiration, 209–211
 advanced molecular methods for,
 210
 blastocyst biopsy, 210–211
 blastomere biopsy, 209–210
 polar body biopsy, 209
 trophectoderm biopsy, 210–211
 historical development of, 207
 HLA typing, 219
 labeling genetic materials with, 211
 mitochondrial DNA disorders, 220
 with next-generation screening, 215,
 217
 PGT-A by, 217–219
 non-invasive, 220
 PGT-A
 karyomapping, 218–219
 mosaicism and, 218
 by next-generation screening,
 217–219
 PGT-TM diagnosis and, 218–219
 PGT-M, 218–219
 de novo mutations, 219–220
 karyomapping, 218–219
 for late-onset neurodegenerative
 disorders, 219
 PGT-A diagnosis, 218–219
 PGT-SR, 213–214
 by next-generation screening, 217
 steps in, 207
 with whole exome sequencing, 217
 with whole-genome amplification,
 215–216
 zona pellucida opening, 208–209
 chemical biopsy, 208
 contact laser biopsy, 208–209
 mechanical opening, 208
 premature adrenarche, 8

Index

- primordial germ cells (PGCs), 3
 prostate gland, 23
 puberty, reproductive system and
 adrenarche, 8
 cortisol production, 8
 dehydroepiandrosterone, 8
 DHES, 8
 premature, 8
 age of onset, by gender, 8
 central nervous system and, 8
 in females, hormonal regulation in,
 28
 gonadarche
 arcuate nuclei, 8–9
 follicle-stimulating hormone, 11
 GnRH-secreting neurons, 9–11
 hypothalamic-pituitary axis, 8–11
 kisspeptin receptors, 8–9
 luteinizing hormone, 8–9, 11
 Kallmann's syndrome and, 9–10
 PVS. *See* penile vibratory stimulation
 PZD. *See* partial zona dissection

 quinagolide, 81

 reproductive aging
 in females, 46–49
 antral follicle count, 49
 artificial reproductive
 technologies, 46, 48
 chromosomal abnormalities, 48
 estradiol declines, 47
 inhibin-B declines, 47
 menopause, 46–47, 53
 mitochondrial DNA instability, 48
 oocyte quality and, 48
 shorter follicular phase, 47–48
 in males, 24–25
 androgen deficiency, 24
 andropause, 24
 late-onset hypogonadism, 24
 potency and sexual interest and,
 decline in, 25
 testosterone levels, decreases in,
 24
 reproductive systems, development of.
 See also female reproductive
 system; male reproductive
 system; puberty
 at embryo stage, 4. *See also* fetal
 gonads
 Barr bodies, 3
 sex chromosomes, 3
 fetal ovary, 3–4
 follicle stimulating hormone and,
 4
 germ cell nest breakdown, 4
 Müllerian hormones, 3
 oocyte development, 4, 6
 primordial germ cells in, 3
 stages of development, 3
 Rock, John, 1–2

 Schlegel, Peter, 174
 semenogelin, 23
 seminal vesicles, 23
 semenogelin, 23
 Sertoli cells, 14–15, 20
 follicle-stimulating hormone and,
 14–15
 sex chromosomes, in embryo
 reproductive systems, 3
 sex hormones. *See specific hormones*
 sexually-transmitted diseases (STDs),
 20
 slow cryopreservation, 144
 social artificial reproductive
 technologies, 81
 social oocytes, 149
 somatic cells, in fetal gonad
 development, 3–4
 Spallanzani, Lazzaro, 1, 152
 sperm cells (spermatozoa). *See also*
 animal sperm cells; donation;
 spermatogenesis;
 spermatogonia; spermiogenesis
 acrosome reaction, 23
 capacitation of, 22
 count for, variability in, 19
 cryopreservation of. *See*
 cryopreservation
 dark type A spermatogonia, 16, 17
 discovery of, 21
 in vitro fertilization and. *See in vitro*
 fertilization
 in IVF preparation. *See in vitro*
 fertilization
 motility of, 20
 pale type A spermatogonia, 16, 17
 structure of, 21
 type B spermatogonia, 16–18
 sperm density gradient centrifugation,
 97
 spermatogenesis, 15–19
 dark type A spermatogonia, 16, 17
 DNA condensation, 18–19
 pale type A spermatogonia, 16, 17
 sperm cell count, variability in, 19
 spermiogenesis, 18–19
 stimulation for, with azoospermia,
 176–177
 type B spermatogonia, 16–18
 spermatogonia
 dark type A, 16, 17
 pale type A, 16, 17
 type B, 16–18
 spermatogonial stem cells (SSCs),
 154
 spermatozoa. *See* sperm cells
 spermiogenesis, 18–19

 SRD5A,2 deficiencies. *See* steroid
 5-alpha-reductase 2 deficiencies
 SSCs. *See* spermatogonial stem cells
 STDs. *See* sexually-transmitted
 diseases
 stem cells. *See* spermatogonial stem
 cells
 Steptoe, Patrick, 1–2
 steroid 5-alpha-reductase 2 (SRD5A2)
 deficiencies, 202
 stroma cells, 34
 subzonal insemination (SUZI), 103
 surrogacy, surrogates and
 access to, 190
 ethical debates over, 189–190
 gestational, 188
 cycles of, 188
 legal elements of, 188
 Mayer-Rokitansky-Kuster-Hauser
 syndrome and, 188–189
 for non-traditional couples and
 singles, 188
 pregnancy success rates for, 188
 process of, 189
 recipient profile, 188–189
 risk factors with, 189
 traditional, 188
 SUZI. *See* subzonal insemination
 swim-down technique, for sperm
 preparation in IVF, 97
 swim-up technique, for sperm
 preparation in IVF, 96

 TA. *See* testicular aspiration
 TDF. *See* testes-determining factor
 TE biopsy. *See* trophoctoderm biopsy
 TESA. *See* testicular sperm aspiration
 “test tube babies,” 1–2
 testes, 13–15
 Leydig cells, 13–14
 Sertoli cells, 14–15, 20
 structure of, 15
 testosterone secretion patterns, 15
 testes-determining factor (TDF), 4–5
 testicles, biopsy of. *See also*
 azoospermia
 types of, 176
 testicular aspiration (TA), 153–154
 testicular fine-needle aspiration
 (TFNA), 171–172
 testicular germ cell tumor (TGCT), 172
 testicular microdissection (mTESE),
 174–176
 testicular sperm aspiration (TESA),
 171–172
 testicular tissue banking, 154
 testosterone
 in fetal gonad development, 5–6
 in Leydig cells, bioavailability of,
 13

- reproductive aging in males and, decrease in production of, 24
- in testes, secretion patterns for, 15
- tetrapronuclear zygotes, 116, 118
- TFNA. *See* testicular fine-needle aspiration
- TGCT. *See* testicular germ cell tumor
- thawing processes, in cryopreservation, 149–150
- for ovarian tissue, 151
- theory of Homunculus, 2
- IVF and, 1
- traditional surrogacy, 188
- translocations, in chromosomes, 196
 - balanced, 196
 - unbalanced, 196
- transrectal ultrasound (TRUS), 171
- transvaginal ultrasound-guided follicular aspiration, 185
- tripronuclear zygotes, 116, 118
- Trisomy X. *See* XXX syndrome
- trophectoderm (TE) biopsy, 210–211
- trophoblast invasion, 61–62
- TRUS. *See* transrectal ultrasound
- Turner syndrome, 199
- two-cell theory, for hormonal ovarian treatment, 71
- two-gonadotropin theory, 71
- type B spermatogonia, 16–18
- unbalanced translocations, in chromosomes, 196
- uniparental disomy, 196–197
- uterus, 31
 - catheter use in, depth of, in embryo transfer, 133–134
 - structure of, 31
 - vaginal microbiota, 31
- vagina, 28–31
 - microbiota in, 28–31
- vaginal microbiota (VMB), 28–31
- van Leeuwenhoek, Anton van, 21
- vitrification methods, for cryopreservation, 145, 148
 - with ovarian tissue, 151
- VMB. *See* vaginal microbiota
- WES. *See* whole exome sequencing
- WGA. *See* whole-genome amplification
- whole exome sequencing (WES), 217
- whole-genome amplification (WGA), 215–216
- X chromosome
 - inactivation of, 196
 - mutations of, 195–196
- XXX syndrome (Trisomy X), 199
- Y chromosome microdeletions, 200–201
- Y0 syndrome, 199–200
- zona pellucida opening, 208–209
 - chemical biopsy, 208
 - contact laser biopsy, 208–209
 - mechanical opening, 208
- zygotes
 - cryopreservation of, 147
 - thawing processes for, 149–150
 - in embryo culture, 116–118, 121
 - tetrapronuclear zygotes, 116, 118
 - tripronuclear zygotes, 116, 118